ES2158938T3 - Derivados de aminoquinazolina que tienen actividad alfa-antagonistas. - Google Patents

Derivados de aminoquinazolina que tienen actividad alfa-antagonistas.

Info

Publication number
ES2158938T3
ES2158938T3 ES95911342T ES95911342T ES2158938T3 ES 2158938 T3 ES2158938 T3 ES 2158938T3 ES 95911342 T ES95911342 T ES 95911342T ES 95911342 T ES95911342 T ES 95911342T ES 2158938 T3 ES2158938 T3 ES 2158938T3
Authority
ES
Spain
Prior art keywords
alfa
antagonist activity
aminoquinazoline derivatives
compounds
derivatives
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Lifetime
Application number
ES95911342T
Other languages
English (en)
Inventor
Amedeo Leonardi
Gianni Motta
Carlo Boi
Rodolfo Testa
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Recordati SA
Original Assignee
Recordati SA
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Recordati SA filed Critical Recordati SA
Application granted granted Critical
Publication of ES2158938T3 publication Critical patent/ES2158938T3/es
Anticipated expiration legal-status Critical
Expired - Lifetime legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/04—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings directly linked by a ring-member-to-ring-member bond
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/02—Drugs for disorders of the urinary system of urine or of the urinary tract, e.g. urine acidifiers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/08—Drugs for disorders of the urinary system of the prostate
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A61P27/06—Antiglaucoma agents or miotics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/06—Antihyperlipidemics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/12—Antihypertensives
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D239/00—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings
    • C07D239/70—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings condensed with carbocyclic rings or ring systems
    • C07D239/72—Quinazolines; Hydrogenated quinazolines
    • C07D239/95—Quinazolines; Hydrogenated quinazolines with hetero atoms directly attached in positions 2 and 4

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Engineering & Computer Science (AREA)
  • Ophthalmology & Optometry (AREA)
  • Urology & Nephrology (AREA)
  • Hematology (AREA)
  • Cardiology (AREA)
  • Obesity (AREA)
  • Diabetes (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Endocrinology (AREA)
  • Reproductive Health (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
  • Steroid Compounds (AREA)

Abstract

NUEVOS DERIVADOS DE QUINAZOLINIL-AMINO UTILES COMO BLOQUEADORES ADRENORECEPTORES {AL}{SUB,1}. ESTOS COMPUESTOS PUEDEN SER USADOS COMO AGENTES TERAPEUTICOS PARA TRATAR AFECCIONES Y ENFERMEDADES RELACIONADAS CON LA HIPERACTIVIDAD DEL SISTEMA ADRENERGICO {AL}, COMO, POR EJEMPLO, HIPERTENSION ARTERIAL, HIPERBLASIA BENIGNA DE PROSTATA (HBP), PRESION INTRAOCULAR ALTA E HIPERCOLESTEROLEMIA. TAMBIEN SE DESCRIBEN LOS PROCESOS PARA LA PREPARACION DE DICHOS COMPUESTOS DE ARRIBA.
ES95911342T 1994-03-18 1995-03-17 Derivados de aminoquinazolina que tienen actividad alfa-antagonistas. Expired - Lifetime ES2158938T3 (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
ITMI940506A IT1270993B (it) 1994-03-18 1994-03-18 Derivati chinzolilamminici attivi come alfa-antagonisti

Publications (1)

Publication Number Publication Date
ES2158938T3 true ES2158938T3 (es) 2001-09-16

Family

ID=11368249

Family Applications (1)

Application Number Title Priority Date Filing Date
ES95911342T Expired - Lifetime ES2158938T3 (es) 1994-03-18 1995-03-17 Derivados de aminoquinazolina que tienen actividad alfa-antagonistas.

Country Status (15)

Country Link
US (1) US5798362A (es)
EP (1) EP0750614B1 (es)
JP (1) JP3683911B2 (es)
AT (1) ATE201400T1 (es)
AU (1) AU1894895A (es)
DE (1) DE69521037T2 (es)
DK (1) DK0750614T3 (es)
ES (1) ES2158938T3 (es)
GR (1) GR3036443T3 (es)
IL (1) IL113024A (es)
IT (1) IT1270993B (es)
PT (1) PT750614E (es)
TW (1) TW416951B (es)
WO (1) WO1995025726A1 (es)
ZA (1) ZA952208B (es)

Families Citing this family (15)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5747490A (en) * 1995-09-29 1998-05-05 Merck & Co., Inc. Alpha 1b adrenergic receptor antagonists
AU7692896A (en) * 1995-12-01 1997-06-27 Novartis Ag Quinazolin-2,4-diazirines as NPY receptor antagonist
IT1286302B1 (it) * 1996-04-10 1998-07-08 Rotta Research Lab Chinazoline-4-amino-2-(piperidino-1-il-4-sostituite) ad attivita' anti-ipertensiva, procedimento per la loro preparazione e loro uso
GB9700504D0 (en) * 1997-01-11 1997-02-26 Pfizer Ltd Pharmaceutical compounds
GB9711650D0 (en) 1997-06-05 1997-07-30 Pfizer Ltd Compounds useful in therapy
US7186726B2 (en) * 1998-06-30 2007-03-06 Neuromed Pharmaceuticals Ltd. Preferentially substituted calcium channel blockers
US6355641B1 (en) 1999-03-17 2002-03-12 Syntex (U.S.A.) Llc Oxazolone derivatives and uses thereof
IT1312310B1 (it) * 1999-05-07 2002-04-15 Recordati Ind Chimica E Farma Uso di antagonisti selettivi del recettore adrenergico a 1b per ilmiglioramento della disfunzione sessuale
ITMI20012060A1 (it) * 2001-10-05 2003-04-05 Recordati Chem Pharm Nuovi eterocilcli n-acilati
US20040072839A1 (en) * 2002-06-14 2004-04-15 Amedeo Leonardi 1-Phenylalkylpiperazines
US7071197B2 (en) 2002-06-14 2006-07-04 Recordati S.A. N,N-disubstituted diazocycloalkanes
US20040058962A1 (en) * 2002-06-14 2004-03-25 Amedeo Leonardi Phenylalkylamines and pyridylalkylamines
EP1695961A4 (en) * 2003-12-17 2007-10-24 Takeda Pharmaceutical UREA DERIVATIVE, METHOD FOR THE PRODUCTION AND THEIR USE
US20060264442A1 (en) * 2005-05-18 2006-11-23 Allergan, Inc. Methods for the treatment of ocular and neurodegenerative conditions in a mammal
AU2013277154A1 (en) 2012-06-20 2014-12-18 Jonathan E. Grob Complement pathway modulators and uses thereof

Family Cites Families (14)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE925468C (de) * 1941-08-13 1955-03-21 Hoechst Ag Verfahren zur Herstellung von ª†, ª†-Diaryl-propyl-aminen
GB679676A (en) * 1950-04-03 1952-09-24 Dow Chemical Co Improved method for the production of salts of aromatic-oxy-aliphatic carboxylic acids
US3511836A (en) * 1967-12-13 1970-05-12 Pfizer & Co C 2,4,6,7-tetra substituted quinazolines
US3635979A (en) * 1969-09-29 1972-01-18 Pfizer Certain 6- and/or 7-alkoxy-substituted-2 4-bis(disubstituted amino) quinazolines
DE2143730A1 (de) * 1971-09-01 1973-03-08 Byk Gulden Lomberg Chem Fab Substituierte pyridine, verfahren zu deren herstellung und sie enthaltende arzneimittel
US4044136A (en) * 1972-09-09 1977-08-23 Pfizer Inc. Aminoquinazoline therapeutic agents
US4026894A (en) * 1975-10-14 1977-05-31 Abbott Laboratories Antihypertensive agents
US4062844A (en) * 1976-09-20 1977-12-13 Pfizer Inc. Process for preparing hypotensive 2-(4-aroylpiperazin-1-yl)-amino-6,7-dimethoxyquinazolines
FR2389614A1 (en) * 1977-05-05 1978-12-01 Synthelabo Antihypertensive 2,4-di:amino-quinazoline(s) - prepd. from a 2-halo-4-amino-quinazoline and a secondary amine
US4607034A (en) * 1979-10-29 1986-08-19 Mitsubishi Yuka Pharmaceutical Co., Ltd. Quinazoline derivatives and pharmaceutical composition thereof
GB2068961B (en) * 1980-02-13 1983-11-30 Sankyo Co Quinazoline derivatives
CS236097B1 (en) * 1983-06-01 1985-05-15 Jan Koenig Acylderivatives of 2-piperazinochinazoline and method of their preparation
AT384218B (de) * 1985-12-04 1987-10-12 Gerot Pharmazeutika Verfahren zur herstellung von neuen chinazolin-derivaten
US5110927A (en) * 1987-12-31 1992-05-05 The United States Of America As Represented By The Department Of Health And Human Services Prazosin analog with increased selectivity and duration of action

Also Published As

Publication number Publication date
TW416951B (en) 2001-01-01
ATE201400T1 (de) 2001-06-15
PT750614E (pt) 2001-10-31
US5798362A (en) 1998-08-25
EP0750614A1 (en) 1997-01-02
IT1270993B (it) 1997-05-26
EP0750614B1 (en) 2001-05-23
DE69521037T2 (de) 2001-10-25
GR3036443T3 (en) 2001-11-30
DK0750614T3 (da) 2001-09-10
AU1894895A (en) 1995-10-09
JPH09511238A (ja) 1997-11-11
ITMI940506A1 (it) 1995-09-18
ITMI940506A0 (it) 1994-03-18
WO1995025726A1 (en) 1995-09-28
DE69521037D1 (de) 2001-06-28
ZA952208B (en) 1995-12-28
IL113024A0 (en) 1995-06-29
IL113024A (en) 2000-07-26
JP3683911B2 (ja) 2005-08-17

Similar Documents

Publication Publication Date Title
ATE279181T1 (de) Verwendung von 5ht-6 antagonisten zur behandlung adhd
ES2149971T3 (es) Derivados 5-sustituidos del acido micofenolico.
DE69822665D1 (de) Verwendung von 9-desoxy-2',9-alpha-methano-3-oxa-4,5,6-trinor-3,7-(1',3'-interphenylen)-13,14-dihydroprostaglandin-f1 zur behandlung von peripheren vaskulären erkrankungen
ES2167377T3 (es) Derivados de piridina farmacologicamente activos y procedimientos para la preparacion de los mismos.
EA200000723A1 (ru) Производные 2-(пурин-9-ил)-тетрагидрофуран-3,4-диола
EA200001224A1 (ru) Производные 2-(пурин-9-ил)-тетрагидрофуран-3,4-диола
EA199900494A1 (ru) Производные 2-(пурин-9-ил)-тетрагидрофуран-3,4-диола
EA200001223A1 (ru) Производные 2-(пурин-9-ил)-тетрагидрофуран-3,4-диола
DE3774918D1 (de) Cancerostatisches mittel.
ES2170141T3 (es) 4-aminoderivados del acido micofenolico con actividad inmunosupresora.
DE59611341D1 (de) Verwendung von saccharid-konjugaten
ES2168359T3 (es) Acido micofenolico 6-sustituido y derivados con actividad inmunosupresora.
DE69631478D1 (de) Verwendung von vitamin d4-derivaten zur behandlung von hauterkrankungen
ATE181913T1 (de) 2-(2-amino-3-methoxyphenyl)-4-oxo-4h-(1)- benzopyran für die behandlung von proliferativer erkrankungen
ATE411026T1 (de) Mittel zur behandlung der alzheimer-krankheit
DE69625691D1 (de) Verabreichung von peptidylheterocyclen zur behandlung von thrombin in zusammenhang stehenden krankheiten
UA70925C2 (uk) Спосіб лікування естрогенстимульованого раку
ATE321548T1 (de) Verwendung von statin zur behandlung von hauterkrankungen
BRPI0413574A (pt) aplicação de polipeptìdeos da famìlia cupredoxina na terapia do cáncer
ATE238792T1 (de) Verwendung von makroliden zur behandlung von glaukom
NO971341D0 (no) Promoter for reseptor tyrosinkinase TIE
IT1270993B (it) Derivati chinzolilamminici attivi come alfa-antagonisti
ATE83376T1 (de) Chinolinylaether tetrazole als mittel zur behandlung von hyperempfindlichen krankheiten.
DE69918972D1 (de) Verwendung von nmda-antagonisten und/oder natriumkanalantagonisten zur behandlung von entzündlichen erkrankungen
EA200000242A1 (ru) Применение фанхинона для лечения болезни альцгеймера

Legal Events

Date Code Title Description
FG2A Definitive protection

Ref document number: 750614

Country of ref document: ES